

ASX Release

Despatch of Pro-rata Rights Issue Offer Documents

6 June 2016, Melbourne, Australia: Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) is pleased to advise that the following documents in relation to its Pro-rata Rights Issue Entitlement Offer (**Offer**) have been despatched to eligible shareholders today:

- Pro-rata Rights Issue Replacement Prospectus (**Replacement Prospectus**); and
- Entitlement and Acceptance Form.

PTX confirms that the Offer contained in the Replacement Prospectus is now open and will still close as previously advised at 5.00pm (Melbourne time) on 21 June 2016, being the last date for receipt of Entitlement and Acceptance Forms and payment (as stated in the indicative timetable in the Replacement Prospectus). As detailed in the Replacement Prospectus, eligible shareholders will be able to apply for securities in excess of their entitlement via the Top Up Facility.

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (**Moffitt**) under the leadership of Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Paul Hopper
Executive Director
Prescient Therapeutics Limited
+61 406 671 515